Hundreds of thousands of people with type 2 diabetes could benefit if the medicines regulator approves a new weekly jab which cuts the number of injections needed by 86 per cent.
The National Institute for Health and Care Excellence (NICE) has recommended a weekly treatment which reduces the annual number of insulin injections from 365 to 52. However, the treatment is yet to be approved by the Medicines and Healthcare Products Regulatory Agency (MHRA).
NICE approved insulin efsitora alfa in final draft guidance on Thursday.
Health officials said they are awaiting the MHRA’s ruling on the treatment “to understand whether it could be rolled out on the NHS”.
The treatment, also known as Onswik and made by Eli Lilly, is said to work as well as daily injections but only needs to be injected once a week.
Officials said the reduction will particularly benefit people who need help injecting insulin, including frailer people and those with sight loss, limited hand movement, learning disabilities, people who have difficulty following the steps involved or those who struggle to stick to their treatment regimen.
Source: The Independent, 20 August 2026
Recommended Comments
Create an account or sign in to comment